Assess Lot-to-Lot Consistency of 3 Lots (Double Blind Design) of GSK Biologicals' 10-Valent Pneumococcal Vaccine and Evaluate Non-Inferiority to Prevenar (Single Blind Design) When Administered as 3-Dose Primary Immunization Course Before 6 Months of Age.

Trial Profile

Assess Lot-to-Lot Consistency of 3 Lots (Double Blind Design) of GSK Biologicals' 10-Valent Pneumococcal Vaccine and Evaluate Non-Inferiority to Prevenar (Single Blind Design) When Administered as 3-Dose Primary Immunization Course Before 6 Months of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; DTaP vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Pertussis; Pneumococcal infections; Streptococcal infections; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top